Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

A. Craig Lockhart, MD, MHS
Published: Friday, Jan 03, 2020



A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Immunotherapy has generated a lot of excitement in oncology. As such, there is a lot of interest in investigating combinations with immunotherapy. There is also evidence indicating that TKIs could enhance the immune microenvironment, leading to enhanced responses. Combinations of the like with regorafenib and TAS-102 may have the same effect, says Lockhart.

In addition, the optimal sequence of these agents is under evaluation. For example, in the ongoing phase II REVERCE trial, patients with KRAS exon 2 wild-type mCRC will be randomized to receive sequential therapy with regorafenib followed by cetuximab (Erbitux) or the reverse sequence following standard chemotherapy, says Lockhart. Such studies will have to be supplemented with biomarker analysis before the paradigm changes, he concludes.
SELECTED
LANGUAGE


A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Immunotherapy has generated a lot of excitement in oncology. As such, there is a lot of interest in investigating combinations with immunotherapy. There is also evidence indicating that TKIs could enhance the immune microenvironment, leading to enhanced responses. Combinations of the like with regorafenib and TAS-102 may have the same effect, says Lockhart.

In addition, the optimal sequence of these agents is under evaluation. For example, in the ongoing phase II REVERCE trial, patients with KRAS exon 2 wild-type mCRC will be randomized to receive sequential therapy with regorafenib followed by cetuximab (Erbitux) or the reverse sequence following standard chemotherapy, says Lockhart. Such studies will have to be supplemented with biomarker analysis before the paradigm changes, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x